Announcement • Jun 30
Jianzhijia Pharmaceutical Chain Group Co., Ltd. to Report First Half, 2026 Results on Aug 27, 2026 Jianzhijia Pharmaceutical Chain Group Co., Ltd. announced that they will report first half, 2026 results on Aug 27, 2026 Declared Dividend • Jun 08
Dividend of CN¥1.27 announced Shareholders will receive a dividend of CN¥1.27. Ex-date: 12th June 2026 Payment date: 12th June 2026 Dividend yield will be 7.1%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is not covered by earnings (124% earnings payout ratio). However, it is well covered by cash flows (18% cash payout ratio). The dividend has increased by an average of 7.8% per year over the past 5 years and payments have been stable during that time. The company's earnings per share (EPS) would need to grow by 38% to bring the payout ratio under control. However, EPS has declined by 14% over the last 5 years so the company would need to reverse this trend. New Risk • May 17
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.7x net interest cover). Earnings have declined by 5.3% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2025 fiscal period end). Dividend is not well covered by earnings (133% payout ratio). Profit margins are more than 30% lower than last year (1.4% net profit margin). Announcement • Apr 28
Jianzhijia Pharmaceutical Chain Group Co., Ltd., Annual General Meeting, May 19, 2026 Jianzhijia Pharmaceutical Chain Group Co., Ltd., Annual General Meeting, May 19, 2026, at 13:30 China Standard Time. Location: The Company's Meeting Room, Kunming, Yunnan China Announcement • Mar 30
Jianzhijia Pharmaceutical Chain Group Co., Ltd. to Report Q1, 2026 Results on Apr 28, 2026 Jianzhijia Pharmaceutical Chain Group Co., Ltd. announced that they will report Q1, 2026 results on Apr 28, 2026 Announcement • Dec 26
Jianzhijia Pharmaceutical Chain Group Co., Ltd. to Report Fiscal Year 2025 Results on Apr 28, 2026 Jianzhijia Pharmaceutical Chain Group Co., Ltd. announced that they will report fiscal year 2025 results on Apr 28, 2026 Reported Earnings • Nov 03
Third quarter 2025 earnings released: EPS: CN¥0.18 (vs CN¥0.24 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.18 (down from CN¥0.24 in 3Q 2024). Revenue: CN¥2.09b (down 7.0% from 3Q 2024). Net income: CN¥28.2m (down 26% from 3Q 2024). Profit margin: 1.3% (down from 1.7% in 3Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings. Announcement • Sep 30
Jianzhijia Pharmaceutical Chain Group Co., Ltd. to Report Q3, 2025 Results on Oct 30, 2025 Jianzhijia Pharmaceutical Chain Group Co., Ltd. announced that they will report Q3, 2025 results on Oct 30, 2025 New Risk • Sep 05
New major risk - Revenue and earnings growth Earnings have declined by 2.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.7x net interest cover). Earnings have declined by 2.6% per year over the past 5 years. Minor Risks Dividend is not well covered by earnings (123% payout ratio). Profit margins are more than 30% lower than last year (1.5% net profit margin). Announcement • Jun 30
Jianzhijia Pharmaceutical Chain Group Co., Ltd. to Report First Half, 2025 Results on Aug 29, 2025 Jianzhijia Pharmaceutical Chain Group Co., Ltd. announced that they will report first half, 2025 results on Aug 29, 2025 Declared Dividend • Jun 15
Dividend of CN¥1.10 announced Shareholders will receive a dividend of CN¥1.10. Ex-date: 18th June 2025 Payment date: 18th June 2025 Dividend yield will be 5.0%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is not covered by earnings (155% earnings payout ratio). However, it is well covered by cash flows (49% cash payout ratio). The dividend has increased by an average of 6.0% per year over the past 4 years and payments have been stable during that time. The company's earnings per share (EPS) would need to grow by 72% to bring the payout ratio under control. However, EPS has declined by 15% over the last 5 years so the company would need to reverse this trend. New Risk • May 07
New major risk - Financial position The company's interest payments are not well covered by earnings. Net interest cover: 2.4x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.4x net interest cover). Minor Risks Dividend is not well covered by earnings (155% payout ratio). Profit margins are more than 30% lower than last year (1.2% net profit margin). Reported Earnings • May 03
Third quarter 2024 earnings released: EPS: CN¥0.24 (vs CN¥0.78 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.24 (down from CN¥0.78 in 3Q 2023). Revenue: CN¥2.25b (up 4.1% from 3Q 2023). Net income: CN¥38.0m (down 69% from 3Q 2023). Profit margin: 1.7% (down from 5.6% in 3Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Announcement • Apr 29
Jianzhijia Pharmaceutical Chain Group Co., Ltd., Annual General Meeting, May 21, 2025 Jianzhijia Pharmaceutical Chain Group Co., Ltd., Annual General Meeting, May 21, 2025, at 13:30 China Standard Time. Announcement • Mar 28
Jianzhijia Pharmaceutical Chain Group Co., Ltd. to Report Q1, 2025 Results on Apr 29, 2025 Jianzhijia Pharmaceutical Chain Group Co., Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025 Announcement • Dec 27
Jianzhijia Pharmaceutical Chain Group Co., Ltd. to Report Fiscal Year 2024 Results on Apr 29, 2025 Jianzhijia Pharmaceutical Chain Group Co., Ltd. announced that they will report fiscal year 2024 results on Apr 29, 2025 Announcement • Nov 27
Jianzhijia Pharmaceutical Chain Group Co., Ltd. (SHSE:605266) announces an Equity Buyback for CNY 100 million worth of its shares. Jianzhijia Pharmaceutical Chain Group Co., Ltd. (SHSE:605266) announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The shares will be purchased at a price not exceeding CNY 31.69 per share. The repurchased shares will be sold by centralized bidding transactions at an appropriate time in accordance with regulatory requirements. The program will be funded from company's own funds and special loan funds of CNY 70 million from Kunming Branch of China Construction Bank Corporation. The program will be valid for 3 months. New Risk • Nov 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (90% net debt to equity). Share price has been volatile over the past 3 months (10% average weekly change). Profit margins are more than 30% lower than last year (2.5% net profit margin). Valuation Update With 7 Day Price Move • Nov 05
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to CN¥25.90, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 13x in the Consumer Retailing industry in China. Total loss to shareholders of 26% over the past three years. Reported Earnings • Oct 30
Third quarter 2024 earnings released: EPS: CN¥0.24 (vs CN¥0.78 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.24 (down from CN¥0.78 in 3Q 2023). Revenue: CN¥2.25b (up 4.1% from 3Q 2023). Net income: CN¥38.0m (down 69% from 3Q 2023). Profit margin: 1.7% (down from 5.6% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥21.32, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 12x in the Consumer Retailing industry in China. Total loss to shareholders of 39% over the past three years. Announcement • Sep 30
Jianzhijia Pharmaceutical Chain Group Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024 Jianzhijia Pharmaceutical Chain Group Co., Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024 Valuation Update With 7 Day Price Move • Sep 28
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to CN¥22.06, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 12x in the Consumer Retailing industry in China. Total loss to shareholders of 32% over the past three years. Announcement • Sep 20
Jianzhijia Pharmaceutical Chain Group Co., Ltd. (SHSE:605266) announces an Equity Buyback for 1,006,711 shares, representing 0.64% for CNY 30 million. Jianzhijia Pharmaceutical Chain Group Co., Ltd. (SHSE:605266) announces a share repurchase program. Under the program, the company will repurchase up to 1,006,711 shares, representing 0.64% of it's share capital for CNY 30 million worth of its shares. The shares will be purchased at a price not exceeding CNY 29.80 per share. The purpose of the program is to maintain the company's value and shareholders' rights and interests. The program will be funded from company's own funds. The program will be valid for 3 months. The company has 156,736,538 shares issued and outstanding. New Risk • Sep 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (70% net debt to equity). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.4% average weekly change). Profit margins are more than 30% lower than last year (3.5% net profit margin). Valuation Update With 7 Day Price Move • Sep 05
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to CN¥22.99, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 11x in the Consumer Retailing industry in China. Total loss to shareholders of 34% over the past three years. New Risk • Sep 04
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 3.5% Last year net profit margin: 5.0% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks High level of debt (70% net debt to equity). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (3.5% net profit margin). Reported Earnings • Sep 03
Second quarter 2024 earnings released: EPS: CN¥0.069 (vs CN¥0.53 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.069 (down from CN¥0.53 in 2Q 2023). Revenue: CN¥2.17b (flat on 2Q 2023). Net income: CN¥10.6m (down 87% from 2Q 2023). Profit margin: 0.5% (down from 3.8% in 2Q 2023). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings. Buy Or Sell Opportunity • Aug 30
Now 21% overvalued Over the last 90 days, the stock has fallen 53% to CN¥19.45. The fair value is estimated to be CN¥16.08, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Earnings per share has grown by 13%. Revenue is forecast to grow by 49% in 2 years. Earnings are forecast to grow by 52% in the next 2 years. Valuation Update With 7 Day Price Move • Jul 10
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥21.68, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 16x in the Consumer Retailing industry in China. Total loss to shareholders of 45% over the past three years. Announcement • Jun 29
Jianzhijia Pharmaceutical Chain Group Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024 Jianzhijia Pharmaceutical Chain Group Co., Ltd. announced that they will report first half, 2024 results on Aug 30, 2024 Announcement • Jun 22
Jianzhijia Pharmaceutical Chain Group Co., Ltd. (SHSE:605266) announces an Equity Buyback for CNY 30 million worth of its shares. Jianzhijia Pharmaceutical Chain Group Co., Ltd. (SHSE:605266) announces a share repurchase program. Under the program, the company will repurchase up to CNY 30 million worth of class A shares. The shares will be repurchased at a price of not more than CNY 32.34 per share. The shares purchased will be sold. The program will be valid till 3 months. Valuation Update With 7 Day Price Move • Jun 05
Investor sentiment deteriorates as stock falls 21% After last week's 21% share price decline to CN¥39.61, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 22x in the Consumer Retailing industry in China. Total loss to shareholders of 18% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥35.38 per share. Announcement • Apr 29
Jianzhijia Pharmaceutical Chain Group Co., Ltd., Annual General Meeting, May 17, 2024 Jianzhijia Pharmaceutical Chain Group Co., Ltd., Annual General Meeting, May 17, 2024, at 13:30 China Standard Time. Location: The Company Headquarters' Meeting Room, Kunming, Yunnan China Reported Earnings • Apr 28
First quarter 2024 earnings released: EPS: CN¥0.41 (vs CN¥0.59 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.41 (down from CN¥0.59 in 1Q 2023). Revenue: CN¥2.31b (up 6.8% from 1Q 2023). Net income: CN¥52.3m (down 32% from 1Q 2023). Profit margin: 2.3% (down from 3.5% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 25% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Announcement • Mar 30
Jianzhijia Pharmaceutical Chain Group Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024 Jianzhijia Pharmaceutical Chain Group Co., Ltd. announced that they will report Q1, 2024 results on Apr 27, 2024 Valuation Update With 7 Day Price Move • Feb 09
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to CN¥52.66, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 19x in the Consumer Retailing industry in China. Total returns to shareholders of 9.9% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥35.27 per share. Announcement • Dec 29
Jianzhijia Pharmaceutical Chain Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024 Jianzhijia Pharmaceutical Chain Group Co., Ltd. announced that they will report fiscal year 2023 results on Apr 27, 2024 Reported Earnings • Nov 01
Third quarter 2023 earnings released: EPS: CN¥0.94 (vs CN¥0.81 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.94 (up from CN¥0.81 in 3Q 2022). Revenue: CN¥2.16b (up 27% from 3Q 2022). Net income: CN¥120.3m (up 15% from 3Q 2022). Profit margin: 5.6% (down from 6.2% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Consumer Retailing industry in China. Reported Earnings • Aug 26
Second quarter 2023 earnings released: EPS: CN¥1.17 (vs CN¥0.46 in 2Q 2022) Second quarter 2023 results: EPS: CN¥1.17 (up from CN¥0.46 in 2Q 2022). Revenue: CN¥2.17b (up 40% from 2Q 2022). Net income: CN¥81.8m (up 40% from 2Q 2022). Profit margin: 3.8% (in line with 2Q 2022). Reported Earnings • Apr 28
First quarter 2023 earnings released: EPS: CN¥0.77 (vs CN¥0.33 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.77 (up from CN¥0.33 in 1Q 2022). Revenue: CN¥2.17b (up 49% from 1Q 2022). Net income: CN¥76.3m (up 160% from 1Q 2022). Profit margin: 3.5% (up from 2.0% in 1Q 2022). The increase in margin was driven by higher revenue. Valuation Update With 7 Day Price Move • Feb 17
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥92.36, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 23x in the Consumer Retailing industry in China. Total returns to shareholders of 66% over the past year. Valuation Update With 7 Day Price Move • Jan 03
Investor sentiment improved over the past week After last week's 18% share price gain to CN¥84.10, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 23x in the Consumer Retailing industry in China. Total returns to shareholders of 35% over the past year. Valuation Update With 7 Day Price Move • Nov 29
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥91.00, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 23x in the Consumer Retailing industry in China. Total returns to shareholders of 60% over the past year. Board Change • Nov 16
Less than half of directors are independent There are 8 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 8 new directors. 2 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Zhenji Zhao is the most experienced director on the board, commencing their role in 2020. Independent Director Yunhong Guan was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Reported Earnings • Oct 30
Third quarter 2022 earnings released: EPS: CN¥1.06 (vs CN¥0.82 in 3Q 2021) Third quarter 2022 results: EPS: CN¥1.06 (up from CN¥0.82 in 3Q 2021). Revenue: CN¥1.70b (up 32% from 3Q 2021). Net income: CN¥104.8m (up 42% from 3Q 2021). Profit margin: 6.2% (up from 5.7% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Consumer Retailing industry in China. Valuation Update With 7 Day Price Move • Oct 26
Investor sentiment improved over the past week After last week's 19% share price gain to CN¥57.89, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 23x in the Consumer Retailing industry in China. Total returns to shareholders of 7.0% over the past year. Valuation Update With 7 Day Price Move • Jun 07
Investor sentiment deteriorated over the past week After last week's 18% share price decline to CN¥46.12, the stock trades at a trailing P/E ratio of 13.3x. Average trailing P/E is 37x in the Consumer Retailing industry in China. Total loss to shareholders of 46% over the past year. Reported Earnings • Apr 28
First quarter 2022 earnings: EPS and revenues exceed analyst expectations First quarter 2022 results: EPS: CN¥0.43 (down from CN¥0.94 in 1Q 2021). Revenue: CN¥1.45b (up 24% from 1Q 2021). Net income: CN¥29.4m (down 55% from 1Q 2021). Profit margin: 2.0% (down from 5.5% in 1Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.6%. Earnings per share (EPS) also surpassed analyst estimates by 38%. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Oct 31
Third quarter 2021 earnings released: EPS CN¥1.07 (vs CN¥1.16 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥1.29b (up 20% from 3Q 2020). Net income: CN¥73.8m (up 23% from 3Q 2020). Profit margin: 5.7% (up from 5.6% in 3Q 2020). The increase in margin was driven by higher revenue. Valuation Update With 7 Day Price Move • Oct 13
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥81.46, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 26x in the Consumer Retailing industry in China. Announcement • Sep 08
Yunnan Jianzhijia Health-Chain Co., Ltd. announced that it expects to receive CNY 419.999981 million in funding from Yunnan Xiangqun Investment Co., Ltd Yunnan Jianzhijia Health-Chain Co., Ltd. announced a private placement transaction of not more than 6,813,757 A shares, par value of CNY 1 per share to be issued at a price of CNY 61.64 per share for gross proceeds of not more CNY 420,000,000 on September 7, 2021. The transaction will include participation from Yunnan Xiangqun Investment Co., Ltd. The pricing reference date will be the first day of issuance. Issue price for the shares to be issued in the private placement shall not be lower than 80% of the average stock price 20 trading days before the pricing reference date. The securities to be issued in the transaction will have a lock-up period of thirty-six months after issuance completion date. The transaction has been approved in the eighth meeting of the fifth board of directors. The transaction is subject to approval from the shareholders of the company and from China Securities Regulatory Commission. Valuation Update With 7 Day Price Move • May 21
Investor sentiment deteriorated over the past week After last week's 25% share price decline to CN¥83.20, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 28x in the Consumer Retailing industry in China. Is New 90 Day High Low • Mar 15
New 90-day low: CN¥101 The company is down 26% from a price of CN¥137 on 15 December 2020. Underperformed the Chinese market, which is flat over the last 90 days. Lagged the Consumer Retailing industry, which is down 10.0% over the same period. Valuation Update With 7 Day Price Move • Dec 24
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥115, the stock is trading at a trailing P/E ratio of 21.2x, down from the previous P/E ratio of 25.2x. This compares to an average P/E of 35x in the Consumer Retailing industry in China. Valuation Update With 7 Day Price Move • Dec 15
Investor sentiment deteriorated over the past week After last week's 19% share price decline to CN¥137, the stock is trading at a trailing P/E ratio of 25.2x, down from the previous P/E ratio of 31.2x. This compares to an average P/E of 35x in the Consumer Retailing industry in China.